X-ray crystallographic analysis of α-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 230-240

  Mileni, Mauro ^a   Garfunkle, Joie ^a   Ezzili, Cyrine ^a   Kimball, F Scott ^a   Cravatt, Benjamin F ^a   Stevens, Raymond C ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMIDOHYDROLASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; OXAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849116058     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9012196     Document Type: Article

References (95)

1. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme that Degrades Neuromodulatory Fatty Acid Amides. Nature 1996, 384, 83-87.
2. Giang, D. K.; Cravatt, B. F. Molecular Characterization of Human and Mouse Fatty Acid Amide Hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2238-2242.
3. Patricelli, M. P.; Cravatt, B. F. Proteins Regulating the Biosynthesis and Inactivation of Neuromodulatory Fatty Acid Amides. Vit. Horm. 2001, 62, 95-131.
4. Egertova, M.; Cravatt, B. F.; Elphick,M. R. Comparative Analysis of Fatty Acid Amide Hydrolase and CB1 Cannabinoid Receptor Expression in the Mouse Brain: Evidence of a Widespread Role for Fatty Acid Amide Hydrolase in Regulation of Endocannabinoid Signaling. Neuroscience 2003, 119, 481-496.
5. Boger, D. L.; Fecik, R. A.; Patterson, J. E.; Miyauchi, H.; Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Substrate Specificity. Bioorg. Med. Chem. Lett. 2000, 10, 2613-2616.
6. (a) Patricelli, M. P.; Cravatt, B. F. Characterization and Manipulation of the Acyl Chain Selectivity of Fatty Acid Amide Hydrolase. Biochemistry 2001, 40, 6107-6115.
7. (b) Lang, W.; Qin, C.; Lin, S.; Khanolkar, A. D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.; Biegel, D.; Makriyannis, A. Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. J. Med. Chem. 1999, 42, 896-902.
8. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
9. Martin, B. R.; Mechoulam, R.; Razdan, R. K. Discovery and Characterization of Endogenous Cannabinoids. Life Sci. 1999, 65, 573-595.
10. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other "Endocannabinoids". Curr. Med. Chem. 1999, 6, 721-744.
11. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-Acylated Glycerophospholipids and Their Derivatives. Prog. Lipid Res. 1990, 29, 1-43.
12. Boger, D. L.; Henriksen, S. J.; Cravatt, B. F. Oleamide: An Endogenous Sleep-Inducing Lipid and Prototypical Member of a NewClass of Lipid Signaling Molecules. Curr. Pharm. Des. 1998, 4, 303-314.
13. Cravatt, B. F.; Lerner, R. A.; Boger, D. L. Structure Determination of an Endogenous Sleep-Inducing Lipid, cis-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantities of a Natural Product. J. Am. Chem. Soc. 1996, 118, 580-590.
14. (a) Cravatt, B. F.; Prospero-Garcia, O.; Suizdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical Characterization of a Family of Brain Lipids that Induce Sleep. Science 1995, 268, 1506-1509.
15. (b) Lerner, R. A.; Siuzdak, G.; Prospero-Garcia, O.; Henriksen, S. J.; Boger, D. L.; Cravatt, B. F. Cerebrodiene: A Brain Lipid Isolated From Sleep-Deprived Cats. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9505-9508.
16. (a) Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
17. (b) Lambert, D. M.; Fowler, C. J. The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. J. Med. Chem. 2005, 48, 5059-5087.
18. (a) Ahn, K.; McKinney, M. K.; Cravatt, B. F. Enzymatic Pathways that Regulate Endocannabinoid Signaling in the Nervous System. Chem. Rev. 2008, 108, 1687-1707.
19. (b) Ahn, K.; Johnson, D. S.; Cravatt, B. F. Fatty Acid Amide Hydrolase As A Potential Therapeutic Target For The Treatment of Pain and CNS disorders. Exp. Opin. Drug Discovery 2009, 4, 763-784.
20. Seierstad, M.; Breitenbucher, J. G. Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. J. Med. Chem. 2008, 51, 7327-7343.
21. (a) Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of Anxiety Through Blockade of Anandamide Hydrolysis. Nat. Med. 2003, 9, 76-81.
22. (b) Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D. Antidepressant-Like Activity and Modulation of Brain Monaminergic Transmission by Blockage of Anandamide Hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18620-18625.
23. Jayamanne, A.; Greenwood, R.; Mitchell, V. A.; Aslan, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH Inhibitor URB597 in Neuropathic and Inflammatory Chronic Pain Models. Br. J. Pharmacol. 2006, 147, 281-288.
24. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic Acid 3′- or 4′-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure - Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 2004, 47, 4998-5008.
25. (a) Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, Synthesis, and Structure - Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
26. (b) Tarzia, G.; Duranti, A.; Gatti, G.; Piersanti, G.; Tontini, A.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Mor, M.; Kathuria, S.; Piomelli, D. Synthesis and Structure - Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring. ChemMedChem. 2006, 1, 130-139.
27. (c) Mor, M.; Lodola, A.; Rivara, S.; Vaconido, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Oiersanti, G.; Clapper, J. R.; King, A. R.; Tarzia, G.; Piomelli, D. Synthesis and Quantitative Structure - Activity Relationships of Fatty Acid Amide Hydrolase Inhibitors: Modulation at the N-Portion of Biphenyl-3-yl Alkylcarbamates. J. Med. Chem. 2008, 51, 3487-3498.
28. (a) Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta,M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Normanbhoy, T.; Alexander, J. P.; Cravatt, B. F. A Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity. Biochemistry 2007, 46, 13019-13030.
29. (b) Johnson, D. S.; Ahn, K.; Kesten, S.; Lazerwith, S. E.; Song, Y.; Morris, M.; Fay, L.; Gregory, T.; Stiff, C.; Dunbar, J. B., Jr.; Liimatta, M.; Beidler, D.; Smith, S.; Nomanbhoy, T. K.; Cravatt, B. F. Benzothiophene Piperazine and Piperidine Urea Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg. Med. Chem. Lett. 2009, 19, 2865-2869.
30. (a) Abouab-Dellah, A.; Burnier, P.; Hoornaert, C.; Jeunesse, J.; Puech, F. (Sanofi). Derivatives of Piperidinyl- and Piperazinylalkyl Carbamates, Preparation Methods and Application in Therapeutics. WO 2004/099176, 2004.
31. (b) Abouab-Dellah, A.; Almario, G. A.; Froissant, J.; Hoornaert, C. (Sanofi). Aryloxyalkylcarbamate Derivatives, Including Piperidine Carbamates, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. WO 2005/077898, 2005.
32. (c) Abouab-Dellah, A.; Almario, G. A.; Hoornaert, C.; Li, A. T. (Sanofi). 1-Piperazine and 1-Homopiperazine Derivatives, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. WO 2005/070910, 2005.
33. (d) Abouab-Dellah, A.; Almario, G. A.; Hoornaert, C.; Li, A. T. (Sanofi). Alkyl-(homo)piperazine-carboxylate Derivatives, Their Preparation and Use as Fatty Acid Amide Hydrolase (FAAH) Inhibitors for Treating FAAH-Related Pathologies. WO 2007/027141, 2007.
34. (a) Sit, S. Y.; Xie, K.; Deng, H. (Bristol-Myers Squibb). Preparation of (Hetero)aryl Carbamates and Oximes as Fatty Acid Amide Hydrolase InhibitorsWO2003/06589, 2003.
35. (b) Sit, S. Y.; Xie, K. (Bristol-Myers Squibb). Preparation of Bis Arylimidazolyl Fatty Acid Amide Hydrolase Inhibitors for Treatment of Pain. WO 2002/087569, 2002.
36. (c) Sit, S. Y.; Conway, C.; Bertekap, R.; Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2007, 17, 3287-3291.
37. (a) Apodaca, R.; Breitenbucher, J. G.; Pattabiraman, K.; Seierstad, M.; Xiao, W. (J&J). Piperazinyl and Piperidinyl Ureas as Modulators of Fatty Acid Amide Hydrolase, US 2006/0173184, 2006.
38. (b) Apodaca, R.; Breitenbucher, J. G.; Pattabiraman, K.; Seierstad, M.; Xiao,W. (J&J). Preparation of Thiadiazolylpiperazine Carboxamides as Modulators of Fatty Acid Amide Hydrolase (FAAH).US 2007/004741, 2007.
39. (c) Keith, J.M.;Apodaca,R.; Xiao,W.; Seierstad, M.; Pattabiraman, K.; Wu, J.; Webb, M.; Karbarz, M. J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C.-S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J. G. Thiadiazolopiperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2008, 18, 4838-4843.
40. (d) Karbarz, M. J.; Luo, L.; Chang, L.; Tham, C.-S.; Palmer, J. A.;Wilson, S. J.; Wennerholm, M. L.; Brown, S. M.; Scott, B. P.; Apodaca, R. L.; Keith, J. M.; Wu, J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Biochemical and Biological Properties of 4-(3-Phenyl[1,2,4]-thiadiazol-5-yl) piperazine-1-carboxylic Acid Phenylamide. A Mechanism-based Inhibitor of Fatty Acid Amide Hydrolase. Anesth. Analg. 2009, 108, 316-329.
41. (a) Matsumoto, T.; Kori, M.; Miyazaki, J.; Kiyota, Y. (Takeda). Preparation of Piperidinecarboxamides and Piperazinecarboxamides as Fatty Acid Amide Hydrolase (FAAH) Inhibitors. WO 2006054652, 2006.
42. (b) Matsumoto, T.; Kori, M.; Kouno, M. (Takeda). Preparation of Piperazine-1-carboxamide Derivatives as Brain/Neuronal Cell-Protecting Agents, and Therapeutic Agents for Sleep Disorder. WO 2007020888, 2007.
43. Ishii, T.; Sugane, T.; Maeda, J.; Narazaki, F.; Kakefuda, A.; Sato, K.; Takahashi, T.; Kanayama, T.; Saitoh, C.; Suzuki, J.; Kanai, C. (Astellas). Preparation of Pyridyl Non-Aromatic Nitrogenated Heterocyclic-1-carboxylate Ester Derivatives as FAAHInhibitors, WO 2006/088075, 2006.
44. (a) Moore, S. A.; Nomikos, G. G.; Dickason-Chesterfield, A. K.; Sohober, D. A.; Schaus, J. M.; Ying, B. P.; Xu, Y. C.; Phebus, L.; Simmons, R. M.; Li, D.; Iyengar, S.; Felder, C. C. Identification of a High-Affinity Binding Site Involved in the Transport of Endocannabinoids (LY2183240). Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17852-17857.
45. (b) Alexander, J. P.; Cravatt, B. F. The Putative Endocannabinoid Transport Blocker LY2183240 is a Potent Inhibitor of FAAH and Several Other Brain Serine Hydrolases. J. Am. Chem. Soc. 2006, 128, 9699-9704.
46. Alexander, J. P.; Cravatt, B. F. Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and In Vivo Functional Probes for Enzymes. Chem. Biol. 2005, 12, 1179-1187.
47. For additional FAAH inhibitors, see: (a) Hart, T.; Macias, A. T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Dokurno, P.; Francis, G.; Gibbons, B.; Haymes, T.; Kennett, G.; Lightowler, S.; Mansell, H.; Matassova, N.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Walls, S.; Wong, M.; Roughley, S. Fatty Acid Amide Hydrolase Inhibitors. Surprising Selectivity of Chiral Azetidine Ureas. Bioorg. Med. Chem. Lett. 2009, 19, 4241-4244.
48. (b) Wang, X.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S. P.; Kolasa, T.; Surowy, C.; El Kouhen, O. F.; Muchmore, S.W.; Briono, J. D.; Stewart, A. O. Synthesis and Evaluation of Benzothiazole-based Analogues as Novel, Potent, and Selective Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2009, 52, 170-180.
49. (c) Myllymaki, M. J.; Saario, S. M.; Kataja, A. O.; Castillo-Melendez, J. A.; Nevalainen, T.; Juvonen, R. O.; Jarvinen, T.; Koskinen, A. M. P. Design, Synthesis, and in Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxylphenyl) methanones as Novel Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2007, 50, 4236-4242.
50. (d) Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitor Templates. J. Med. Chem. 2006, 49, 417-425.
51. (e) Saario, S. M.; Poso, A.; Juvonen, R. O.; Jarvinen, T.; Salo-Ahen, O. M. H. Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System. J. Med. Chem. 2006, 49, 4650-4656.
52. (f) Minkkila, A.; Saario, S. M.; Kasnanen, H.; Leppanen, J.; Poso, A.; Nevalainen, T. Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2008, 51, 7057-7060.
53. (g) Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Boger, D. L. Heterocyclic Sulfoxide and Sulfone Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2005, 15, 103-106.
54. (h) Patricelli, M. P.; Patterson, J. E.; Boger, D. L.; Cravatt, B. F. An Endogenous Sleep-Inducing Compound Is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 1998, 8, 613-616.
55. (i) Urbach, A.; Muccioli, G. G.; Stern, E.; Lambert, D. M.; Marchand-Brynaert, J. 3-Alkenyl-2-azetidinones as Fatty Acid Amide Hydrolase Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4163-4167.
56. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase: The Enzyme Responsible for Degradation of Endogenous Oleamide and Anandamide. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5044-5049.
57. Boger, D. L.; Miyauchi, H.; Hedrick, M. P. α-Keto Heterocycle Inhibitors of Fatty Acid Amide Hydrolase: Carbonyl Group Modification and R-Substitution. Bioorg. Med. Chem. Lett. 2001, 11, 1517-1520.
58. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaráes, C. R. W.; Jorgensen,W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Effective as Analgesics. J. Med. Chem. 2005, 48, 1849-1856.
59. Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an Exceptionally Potent and Selective Class of Fatty Acid Amide Hydrolase Inhibitors Enlisting Proteome-Wide Selectivity Screening: Concurrent Optimization of Enzyme Inhibitor Potency and Selectivity. Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428.
60. Romero, F. A.; Hwang, I.; Boger, D. L. Delineation of a Fundamental α-Ketoheterocycle Substituent Effect for Use in the Design of Enzyme Inhibitors. J. Am. Chem. Soc. 2006, 128, 14004-14005.
61. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, B. J.; Cravatt, B. F.; Boger, D. L. Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase. J. Med. Chem. 2007, 50, 1058-1068.
62. Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Structure - Activity Relationships of R-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2007, 50, 3359-3368.
63. Kimball, F. S.; Romero, F. A.; Ezzili, C.; Garfunkle, J.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of R-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2008, 51, 937-947.
64. Garfunkle, J.; Ezzili, C.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of the Central Heterocycle of α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem. 2008, 51, 4392-4403.
65. DeMartino, J. K.; Garfunkle, J.; Hochstatter, D. G.; Cravatt, B. F.; Boger, D. L. Exploration of a Fundamental Substituent Effect of R-Ketoheterocycle Enzyme Inhibitors: Potent and Selective Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2008, 18, 5842-5846.
66. (a) Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase that Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. J. Pharmacol. Exp. Ther. 2004, 311, 441-448.
67. (b) Chang, L.; Luo, L.; Palmer, J. A.; Sutton, S.; Wilson, S. J.; Barbier, A. J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Inhibition of Fatty Acid Amide Hydrolase Produces Analgesia by Multiple Mechanisms. Br. J. Pharmacol. 2006, 148, 102-113.
68. (c) Palmer, J. A.; Higuera, E. S.; Chang, L.; Chaplan, S. R. Fatty Acid Amide Hydrolase Inhibition Enhances the Anti-Allodynic Actions of Endocannabinoids in a Model of Acute Pain Adapted for the Mouse. Neuroscience 2008, 154, 1554-1561.
69. (d) Timmons, A.; Seirestad, M.; Apodaca, R.; Epperson, M.; Pippel, D.; Brown, S.; Chang, L.; Scoot, B.; Webb, M.; Chaplan, S. R.; Breitenbucher, J. G. Novel Ketooxazole Based Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg. Med. Chem. Lett. 2008, 18, 2109-2113.
70. (e) Schlosburg, J. E.; Boger,D. L.; Cravatt, B. F.; Lichtman, A.H. Endocannabinoid Modulation of Scratching Response in an Acute Allergenic Model: A New Prospective Neural Therapeutic Target for Pruritus. J. Pharmacol. Exp. Ther. 2009, 329, 314-323.
71. (f) Kinsey, S. G.; Long, J. Z.; O'Neal, S. T.; Abdulla, R. A.; Poklis, J. L.; Boger, D. L.; Cravatt, B. F.; Lichtman, A. H. Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain. J. Pharmacol. Exp. Ther. 2009, 330, 902-910.
72. (a) McKinney, M. K.; Cravatt, B. F. Structure and Function of Fatty Acid Amide Hydrolase. Annu. Rev. Biochem. 2005, 74, 411-432.
73. (b) McKinney,M. K.; Cravatt, B. F. Evidence For Distinct Roles in Catalysis For Residues of the Serine - Serine - Lysine Catalytic Triad of Fatty Acid Amide Hydrolase. J. Biol. Chem. 2003, 278, 37393-37399.
74. (c) Patricelli, M. P.; Cravatt, B. F. Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family. J. Biol. Chem. 2000, 275, 19177-19184.
75. (d) Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase: Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties. Biochemistry 1999, 38, 9804-9812.
76. (e) Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism. Biochemistry 1999, 38, 14125-14130.
77. (a) Ahn, K.; Johnson, D. S.; Mileni, M.; Beidler, D.; Long, J. Z.; McKinney, M. K.; Weerapana, E.; Sadagopan, N.; Liimatta, M.; Smith, S. E.; Lazerwith, S.; Stiff, C.; Kamtekar, S.; Bhattacharya, K.; Zhang, Y.; Swaney, S.; Van Becelaere, K.; Stevens, R. C.; Cravatt, B. F. Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain. Chem. Biol. 2009, 16, 411-420.
78. (b) Mileni, M.; Johnson, D. S.;Wang, Z.; Everdeen, D. S.; Liimatta, M.; Pabst, B.; Bhattacharya, K.; Nugent, R. A.; Kamtekar, S.; Cravatt, B. F.; Ahn, K.; Stevens, R. C. Structure-Guided Inhibitor Design for Human FAAH by Interspecies Active Site Conversion. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 12820-12824.
79. (c) Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Adaptations in a Membrane Enzyme that Terminates Endocannabinoid Signaling. Science 2002, 298, 1793-1796.
80. Mileni, M.; Garfunkle, J.; DeMartino, J. K.; Cravatt, B. F.; Boger, D. L.; Stevens, R. C. Binding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal Structures. J. Am. Chem. Soc. 2009, 131, 10497-10506.
81. (a) Patterson, J. E.; Ollmann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C.-H.; Lerner, A. E. Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide. J. Am. Chem. Soc. 1996, 118, 5938-5945. See also:
82. (b) Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of Arachidonyl-ethanolamide Hydrolysis. J. Biol. Chem. 1994, 269, 22937-22940.
83. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition. Bioorg. Med. Chem. Lett. 1999, 9, 265-270.
84. Maryanoff, B. E.; Costanzo, M. J. Inhibitors of Proteases and Amide Hydrolases that Employ an R-Ketoheterocycle as a Key Enabling Functionality. Bioorg. Med. Chem. 2008, 16, 1562-1595.
85. (a) Edwards, P. D.; Meyer, E. F. J.; Vijayalakshmi, J.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex Between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-benzoxazole. J. Am. Chem. Soc. 1992, 114, 1854-1863.
86. (b) Edwards, P. D.; Bernstein, P. R. Synthetic Inhibitors of Elastase. Med. Res. Rev. 1994, 14, 127-194.
87. (c) Edwards, P. D.; Zottola, M. A.; Davis, M.; Williams, J.; Tuthill, P. A. Peptidyl α-Ketoheterocyclic Inhibitors of Human Neutrophil Elastase. 3. In Vitro and in Vivo Potency of a Series of Peptidyl R-Ketobenzoxazoles. J. Med. Chem. 1995, 38, 3972-3982.
88. (d) Edwards, P. D.; Andisik, D.W.; Bryant, C. A.; Ewing, B.; Gomes, B.; Lewis, J. J.; Rakiewicz, D.; Steelman, G.; Strimpler, A.; Trainor,D. A.; Tuthill, P. A.; Mauger,R. C.; Veale, C. A.;Wildonger, R. A.;Williams, J. C.;Wolanin, D. J.; Zottola, M. Discovery and Biological Activity of Orally Active Peptidyl Trifluoromethyl Ketone Inhibitors of Human Neutrophil Elastase. J. Med. Chem. 1997, 40, 1876-1885.
89. (a) Guimaráes, C. R. W.; Boger, D. L.; Jorgensen, W. L. Elucidation of Fatty Acid Amide Hydrolase Inhibition by Potent R-Ketoheterocycle Derivatives from Monte Carlo Simulations. J. Am. Chem. Soc. 2005, 127, 17377-17384. See also:
90. (b) Tubert-Brohman, I.; Acevedo, O.; Jorgensen, W. L. Elucidation of Hydrolysis Mechanisms for Fatty Acid Amide Hydrolase and Its Lys142Ala Variant via QM/MM Simulations. J. Am. Chem. Soc. 2006, 128, 16904-16913.
91. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering Potent and Selective Reversible Inhibitors of Enzymes in Complex Proteomes. Nat. Biotechnol. 2003, 21, 687-691.
92. (a) McKinney, M. K.; Cravatt, B. F. Structure-Based Design of a FAAH Variant That Discriminates between the N-Acyl Ethanolamine and Taurine Families of Signaling Lipids. Biochemistry 2006, 45, 9016-9022.
93. (b) Saghatelian, A.; McKinney, M. K.; Bandell, M.; Patapoutian, A.; Cravatt, B. F. A FAAH-Regulated Class of N-Acyl Taurines that Activates TRP Ion Channels. Biochemistry 2006, 45, 9007-9015.
94. (c) Saghatelian, A.; Trauger, S. A.; Want, E. J.; Hawkins, E. G.; Suizdak, G.; Cravatt, B. F. Assignments of Endogenous Substrates to Enzymes by Global Metabolite Profiling. Biochemistry 2004, 43, 14332-14339.
95. Slaymaker, I. M.; Bracey, M.; Mileni, M.; Garfunkle, J.; Cravatt, B. F.; Boger, D. L.; Stevens, R. C. Correlation of Inhibitor Effects on Enzyme Activity and Thermal Stability for the Integral Membrane Protein Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2008, 18, 5847-5850.